WCM Investment Management LLC Takes Position in Emergent Biosolutions Inc (NYSE:EBS)

WCM Investment Management LLC bought a new stake in shares of Emergent Biosolutions Inc (NYSE:EBS) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 79,720 shares of the biopharmaceutical company’s stock, valued at approximately $3,851,000. WCM Investment Management LLC owned approximately 0.16% of Emergent Biosolutions at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the company. Tygh Capital Management Inc. purchased a new stake in shares of Emergent Biosolutions during the second quarter worth approximately $4,636,000. Eagle Asset Management Inc. increased its stake in shares of Emergent Biosolutions by 46.5% during the second quarter. Eagle Asset Management Inc. now owns 306,632 shares of the biopharmaceutical company’s stock worth $14,813,000 after buying an additional 97,374 shares during the period. Swiss National Bank increased its stake in shares of Emergent Biosolutions by 2.7% during the second quarter. Swiss National Bank now owns 81,000 shares of the biopharmaceutical company’s stock worth $3,913,000 after buying an additional 2,100 shares during the period. KBC Group NV purchased a new stake in shares of Emergent Biosolutions during the second quarter worth approximately $126,000. Finally, Fisher Asset Management LLC increased its stake in shares of Emergent Biosolutions by 23.3% during the second quarter. Fisher Asset Management LLC now owns 657,957 shares of the biopharmaceutical company’s stock worth $31,786,000 after buying an additional 124,413 shares during the period. 87.48% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently weighed in on EBS. Cowen restated a “hold” rating and set a $60.00 target price on shares of Emergent Biosolutions in a research note on Wednesday, July 31st. ValuEngine lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, July 17th. Cantor Fitzgerald restated a “buy” rating and set a $75.00 target price on shares of Emergent Biosolutions in a research note on Thursday, May 2nd. Finally, Wells Fargo & Co cut their target price on shares of Emergent Biosolutions to $61.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $70.33.

In other Emergent Biosolutions news, Director Kathryn C. Zoon sold 1,376 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $43.39, for a total value of $59,704.64. Following the transaction, the director now directly owns 24,379 shares in the company, valued at $1,057,804.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.10% of the company’s stock.

Emergent Biosolutions stock traded down $0.32 during mid-day trading on Thursday, hitting $41.78. The company had a trading volume of 8,049 shares, compared to its average volume of 313,144. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of 17.85, a PEG ratio of 0.72 and a beta of 1.60. Emergent Biosolutions Inc has a 1 year low of $39.64 and a 1 year high of $73.89. The company has a quick ratio of 1.53, a current ratio of 2.30 and a debt-to-equity ratio of 0.84. The business has a fifty day moving average of $43.98 and a 200 day moving average of $49.75.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The company had revenue of $243.20 million during the quarter, compared to analysts’ expectations of $217.94 million. Emergent Biosolutions had a negative net margin of 2.04% and a positive return on equity of 6.68%. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.07 earnings per share. Equities analysts anticipate that Emergent Biosolutions Inc will post 3.05 earnings per share for the current year.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.

Featured Story: Put Option

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.